biostudies-literatureUnknown9(2)Lee KWC<h4>Importance</h4>Molecular testing in non-small cell lung cancer (NSCLC) is commonly limited by inadequate tumor sample. Plasma cell-free DNA (cfDNA) genotyping as a complementary test is specific but only moderately sensitive. Genotyping of cfDNA in pleural and pericardial effusion (PE-cfDNA) can further optimize molecular diagnostic yield and reduce the need for repeated biopsies.<h4>Objective</h4>To prospectively validate droplet digital polymerase chain reaction (ddPCR) for detection of sensitizing EGFR variants and acquired Thr790Met variant (T790M) from PE-cfDNA in patients with NSCLC.<h4>Design, setting, and participants</h4>This prospective diagnostic validation study was conducted between September 6, 2016, and January 21, 2021 at 2 major Hong Kong cancer centers. Patients with JAMA oncology261-265https://www.ebi.ac.uk/biostudies/studies/S-EPMC9936333biostudies-literatureTesting for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.PMC9936333Lau YMMok TSKChan OSHChan VWKam KNPGai WLee KWCChan AKCLee CKFung SYHYeung RMWLeung LCheung WFLi MSCfalseTesting for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.<h4>Importance</h4>Molecular testing in non-small cell lung cancer (NSCLC) is commonly limited by inadequate tumor sample. Plasma cell-free DNA (cfDNA) genotyping as a complementary test is specific but only moderately sensitive. Genotyping of cfDNA in pleural and pericardial effusion (PE-cfDNA) can further optimize molecular diagnostic yield and reduce the need for repeated biopsies.<h4>Objective</h4>To prospectively validate droplet digital polymerase chain reaction (ddPCR) for detection of sensitizing EGFR variants and acquired Thr790Met variant (T790M) from PE-cfDNA in patients with NSCLC.<h4>Design, setting, and participants</h4>This prospective diagnostic validation study was conducted between September 6, 2016, and January 21, 2021 at 2 major Hong Kong cancer centers. Patients with 2023-01-01T00:00:00Z2023 Feb2025-04-19T14:32:31.902Z2025-04-19T14:32:31.902ZS-EPMC99363333658028510.1001/jamaoncol.2022.6109